JC Polyomavirus, Molecular, CSF
JC Polyomavirus belongs to the Polyomaviridae family of small (40-45 nm), non-enveloped, icosahedral. naked capsid, double stranded DNA viruses. Serval members of this family can cause human disease including BK virus (hemorrhagic cystitis, nephritis and renal rejection in immunocompromised individuals), Merkel cell polyomavirus (Merkel cell carcinoma), Trichodysplasia spinulosa polyomavirus (trichodysplasia spinulosa) and JC virus.
JC polyomavirus virus is responsible for causing Progressive Multifocal Leukoencephalopathy (PML), a rare yet fatal demyelinating disease of the central nervous system. Around 35-70% of the human population is infected with JCV once in their life. In immunocompetent individuals, it remains latent following primary infection but may produce severe demyelinating and possible oncogenic disease in immunocompromised individuals. Individuals with HIV/AIDS and those undergoing immunomodulatory therapy or being treated with Natalizumab are at high risk for severe JC polyomavirus infection.
PML from JCV presents clinically with progressive focal neurologic deficits including ataxia, hemiparesis, visual field deficits, and cognitive impairment. Histologically, a classical triad of demyelination, abnormal astrocytes, and oligodendrocytes with nuclear inclusions is present. JCV is known to replicate extensively in oligodendrocytes, astrocytes, and microglial cells resulting in cytolytic death and loss of myelin from white matter. There is no specific therapy for PML and treatment is aimed at reducing immunosuppression, stopping Natalizumab and in patients with HIV optimizing their anti-retroviral therapy (ART). The mortality rate for PML is dependent on the underlying immunosuppression and treatment. In patients with HIV, ART has significantly extended survival form months to years but survivors are often left with significant neurologic sequelae. In transplant patients, particularly those with a history of hematologic malignancy the survival is typically between 3 and 8 months. In patients with multiple sclerosis treated with Natalizumab who develop PML have a one-year survival rate of approximately 80%.
JCV can be detected in CSF, blood, urine. Molecular detection of JCV utilizes real-time polymerase chain reaction (PCR) targeting viral protein (VP) 1 gene (Capsid protein) and VP2 (coat protein) gene, in-situ hybridization, and genome sequencing. Real time-PCR represents the first-line diagnostic testing with 70-90% sensitivity and >95% specificity.
- Useful in diagnosing Progressive Multifocal Leukoencephalopathy (PML)
- Aids in identifying the causative agent of meningitis and encephalitis
- A positive result indicates infection with JC polyomavirus
- A negative result indicates no infection with JC polyomavirus
Not detected (Negative)
Cerebrospinal fluid (CSF).
- Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen (preferred): CSF (7 days), Plasma (30 days)
- Acta Neurol Scand. 2017 Nov;136 Suppl 201:37-44. [PMID: 29068484]
- Biol Chem. 2017 Jul 26;398(8):839-855. [PMID: 28493815]
- Rev Med Virol. 2016; 26:102-114. [PMID: 26663440]
- J Neurovirol. 2000 May;6 Suppl 2:S98-S100. [PMID: 10871795]
- APIMS J pathol, microbiol immunol. 2013; 685–727. [PMID: 23781977]
- Procop GW. Molecular Testing for Polyomaviruses. Diagnostic Molecular Pathology. 1st edition. 2017. p(115–122)